FOLH1 and neoplasm: Evans blue (EB) is one compound used for this purpose; thus, [177Lu]Lu-EB-PSMA-617 has been introduced [178], which revealed in a first in human study [179] higher accumulation in metastatic castration-resistant prostate cancer (mCRPC) than [177Lu]Lu-PSMA-617 and that a lower dose of the new radiopharmaceutical appears to be already effective in treating tumours.